Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 17/20 | 0.65 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | NQO1 | P15559 | 2/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753153 | 0.87 | NQO2 (0.66) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526629 | 0.84 | NQO2 (0.67) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL7220854 | 0.82 | NQO2 (0.71) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL7061286 | 0.82 | NQO2 (0.52) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL14291793 | 0.80 | NQO2 (0.69) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526641 | 0.80 | NQO2 (0.80) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL5132229 | 0.79 | NQO2 (0.67) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13526628 | 0.79 | NQO2 (1.00) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL7059879 | 0.79 | NQO2 (0.50) | NQO2SMARCA2NSD2NQO1KEAP1 | |
| SCHEMBL13916795 | 0.78 | NQO2 (0.68) | NQO2SMARCA2NSD2NQO1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664263-B2 | Potent unsymmetrical DNA bifunctional intercalators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-16 | — | — | US | disclosed |
| US-20030203916-A1 | 1,8-NAPHTHALIMIDE IMIDAZO{4,5,1-DE}ACRIDONES WITH ANTI-TUMOR ACTIVITY | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEARTMENT OF | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203916-A1 | 1,8-NAPHTHALIMIDE IMIDAZO{4,5,1-DE}ACRIDONES WITH ANTI-TUMOR ACTIVITY | MKI67, CDKN1A, CCNA1 | NQO2 140/4885SMARCA2 3646/4885NSD2 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.